Objective To assess the long-term patient-reported outcomes and adverse events following surgery using transobturator tension-free vaginal tape (TO-TVT).
Introduction
There is a paucity of data on the long-term outcomes of transobturator tension-free vaginal tape (TO-TVT) in the surgical treatment of female stress urinary incontinence (SUI). In the UK, the National Institute for Health and Clinical Excellence (NICE), and the interim reports on transvaginal mesh for SUI and prolapse surgery, both in Scotland and England, highlighted the lack of long-term outcome data for mid-urethral slings (MUSs) in general, and TO-TVT in particular. [1] [2] [3] They emphasised the importance of directing future research to address this gap in the literature. Long-term data on MUSs are primarily derived from the clinical trials assessing retro-pubic tension-free vaginal tapes (RP-TVT); 4, 5 however, long-term outcomes for TO-TVT are now emerging. 6, 7 Trial registration number and link to the registration web page: The study was registered on www.clinicaltrials.gov with registration number NCT00136071.
The Evaluation of TransObturator Tension free vaginal tapes (E-TOT) study is the largest randomised controlled trial (RCT) assessing the outcomes of TO-TVT (n = 341 women), and the only adequately powered RCT in the literature to compare inside-out versus outside-in approaches. 8 We have previously reported the outcomes at 1 and 3 years of follow-up. 8, 9 At 3 years, the patientreported success rate was 73.1%, with no significant difference between groups (inside-out 73.2% versus outside-in 72.3%; odds ratio, OR 0.927; 95% confidence interval, 95% CI 0.552-1.645; P = 0.796). 9 In the E-TOT study we used the Patient Global Impression of Improvement (PGI-I) scale as the primary outcome, as it provides a robust, validated, and more global review of the treatment outcome, and more fully encompasses the range of benefits and potential harms of the treatment. Several studies have established its validity to assess disease severity, bother, and improvement after treatment in women with SUI.
In this study we aim to assess the long-term outcomes and adverse events following TO-TVT as a whole cohort, and to compare the effectiveness of inside-out versus outside-in approaches.
Methods
The long-term follow-up of the E-TOT RCT (Figure 1 ) was conducted between April 2005 and April 2007 in a tertiary urogynaecology centre in the UK. The E-TOT protocol was registered on www.clinicaltrials.gov and ethics committee approval was obtained for this long-term follow-up. All eligible participants with urodynamic SUI or stress-predominant mixed urinary incontinence (MUI), who failed or declined pelvic floor muscle training, and opted for an MUS procedure within the study period, were invited to participate. Women with pelvic organ prolapse (≥POP-Q stage 2), concomitant surgery, previous pelvic irradiation, and relevant neurological conditions (such as multiple sclerosis) were excluded.
Participants (n = 341) were randomised to undergo either TVT-O (Ethicon Inc., Somerville, NJ, USA) for the insideout approach or TOT-ARIS (Coloplast Corp., Minneapolis, MN, USA) for the outside-in approach. TO-TVT was performed as originally described. 10, 11 Preoperative assessment included urodynamic assessment and completion of the Birmingham Bowel Urinary Symptom-22 questionnaire (BBUQ-22), 12 King's Health Questionnaire (KHQ), 13, 14 and Prolapse Incontinence Sexual Function Questionnaire (PISQ-12).
15 At 1, 3 and 9 years of follow-up, participants were contacted by post and completed the above questionnaires and, in addition, PGI-I, 16 International Consultation on Incontinence Questionnaire -Short Form (ICIQ-SF), 17 Urgency Perception Scale (UPS), 18 and questions on adverse events and further continence surgery.
A total of 314 participants were included in this long-term follow-up; 22 participants who received further continence surgery within the first 3 years were included in this study and considered as treatment failures. A total of 292 participants were contacted between April 2014 and February 2015. Our strategy for non-responders included another round of postal questionnaires. Persistent non-responders received a further short questionnaire and/or phone interview.
Similar to reports at 1 and 3 years of follow-up, the primary outcome was patient-reported success rate based on a response of 'very/much improved' to the PGI-I. Secondary outcomes were further continence surgery, impact on quality of life (QOL), sexual function, adverse events such as groin/thigh pain and tape erosions/extrusions, and risk factors for late failures.
We anticipated a response rate of ≥50%, assuming 180 respondents (with 90 in each arm) and a success rate of 70% for inside-out TVT-O, as reported by Angioli et al. 19 This would give 80% power to detect a 20% difference in the patient-reported success rates between the two groups. Categorical variables were compared using the chi-square test. Within-group comparison was undertaken using Wilcoxon and Mann-Whitney tests. Risk factors for late failures were assessed in a sequential regression model. All statistical analysis was performed using SPSS 22.0 (IBM Corp., Armonk, NY, USA) and GraphPad STATISTICS 2014.
Results
A total of 314 participants were included in this long-term study; seven participants were excluded (either deceased n = 4 or withdrawn n = 3). Long-term follow-up was completed by 208 (outside-in n = 104 versus inside-out n = 104); the adjusted response rate is 67.8% (Figure 1 ). The mean age at follow-up was 61 years, SD 10.12 years (median 59 years; range 41-87 years). The median followup time was 9.2 years (range 81-119 months; mean 109.8 months, SD 15.22 months). All missing data were confirmed to be missing at random and were handled by multiple imputation and sensitivity analysis.
Patient-reported success
The overall patient-reported success rate, defined as 'very/ much improved' on PGI-I, was 71.6%, with no significant difference between groups (outside-in 73.1% n = 76 versus inside-out 70.2% n = 73; P = 0.76; OR 0.867, 95% CI 0.474-1.586). A further 14% (n = 30) reported an 'Improvement'. These results pertained on random multiple imputation and multiple sensitivity analysis ( Table 1 ). The patient-reported success rate using the last observation carried forward for missing data was 72.6%, with no significant differences between groups (outside-in 75.5% versus inside-out 69.9%; P = 0.29; Table 1 ).
Compared with the 1-year outcomes, there was a significant reduction in the patient-reported success rate at 9 years (80 versus 71.6%, P = 0.004); however, compared with the 3-year follow-up, there was only a modest 1.5% reduction over 6 years (73.1 versus 71.6%; Figure 2A ). A number of potential risk factors for 'late failure' (i.e. in the period between follow-up at 3 and 9 years) were analysed, including age, body mass index (BMI), overactive bladder (OAB) symptoms, previous continence surgery, and maximum urethral closure pressure (MUCP); no independent risk factors were identified on sequential regression analysis.
Further analysis for women within the study who did not meet the definition of success (n = 59) showed PGI-I responses of 'improved (n = 30)', 'same (n = 10)', 'worse (n = 10)', 'very much worse (n = 9)'. We further analyzed ICIQ-SF and BBUQ-22 responses in this group, this showed symptoms of MUI in 47 women, symptoms of pure urgency urinary incontinence (UUI) and pure SUI in three and four women, respectively. 
Adverse events
Adverse events were assessed amongst the respondents only (n = 208), and showed a 9.61% de-novo urgency rate, of which 84% were mild or moderate on UPS. Late tape extrusion/erosions, i.e. after 3 years, was reported in 1.9% (n = 4); however, the total erosion/extrusion rate over the period of follow-up in the whole E-TOT cohort is 4.5% (n = 14/314).
Groin or inner thigh pain/discomfort (defined by the patient having any level of thigh and/or groin pain/discomfort) was reported in 4.32% (inside-out n = 4 versus outside-in n = 5): two participants (1%) reported receiving analgesia, whereas one participant (0.4%) underwent complete tape removal for a combination of vaginal extrusion and pain. The latter participant reported a background of arthritis for which she was also receiving analgesia. Table 2 shows all adverse events at 9 years.
Further continence surgery
A total of 25 participants (7.96%) underwent further surgical treatment for SUI over the entire follow-up period in the whole E-TOT cohort (n = 25/314); however, only 1% (n = 3) underwent repeat surgery between the follow-up at 3 and 9 years ( Figure 2B ). The surgical details of the repeat continence surgery and the outcomes are presented in Table S1 : the patient-reported success rate in this group was relatively poorer (65%), however it was difficult to draw meaningful conclusions because of the relatively small cohort and the heterogeneity of the type of further continence surgery performed.
Quality of life and sexual function
The KHQ was completed by 171 participants. Clinically significant improvement in QoL (defined as ≥10 points of improvement) was seen in 76.8%, with no evidence of significant differences between both groups (OR 0.566, 95% CI 0.292-1.202; P = 0.121). A total of 87 participants (44.8%) completed PISQ-12 questionnaires (both pre-and postoperatively). The sexual function score on PISQ-12 showed improvement in 61% and deterioration in 34.5%, with no evidence of any significant difference between groups (P = 0.113; Table S2 ). **Adverse events were assessed among respondents only (n = 208), as one single cohort. ***On checking our records, she had almost a total excision of TVT-O (vaginal portion and up to obturator muscle) because of erosion in lateral vaginal sulcus with growing granulation tissue on top and tenderness. She had a background of arthritis, for which she was already taking regular analgesia.
Discussion
The E-TOT study is the largest RCT to report long-term outcomes for TO-TVT with the ability to compare the patient-reported outcomes at different follow-up points.
Main findings
The results show that the overall patient-reported success rate of TO-TVT was 71.6% at a median follow-up of 9 years, with no significant difference between groups; the results pertained on multiple sensitivity analysis. A further 14% reported an 'improvement'; however, unlike Nilsson et al. 5 , we did not consider 'improved' as a successful outcome, in order to avoid any overestimation of success rates. Nilsson et al. 5 reported on a small population (n = 58) who underwent RP-TVT with 17 years of follow-up; the patient-reported success rate was 87%. The success rate showed a significant reduction compared with results at 1 year, but a clinically insignificant reduction when compared with results at 3 years. A clinically significant improvement in QoL was seen in the majority of patients (76.8%), with no evidence of significant differences between both groups. A total of 8% underwent further continence surgery. Adverse events included a tape extrusion/erosion rate of 4.5%, and groin pain/discomfort in 4.32%, with only 1.4% requiring treatment.
Strengths and limitations
The long-term follow-up for a large homogenous cohort of women and the clinically applicable results are major strengths. The good response rate of 67.8% is quite representative of the whole cohort. The E-TOT RCT is adequately powered, with robust inclusion and exclusion criteria, and standardised postoperative assessment using validated tools. Patient-reported outcomes were obtained by a postal questionnaire that essentially eliminates assessor bias and reduces the participants' visits to hospital, which in turn reduces the attrition rates.
The assessment of adverse events in our study was selfreported, which may be seen as a limitation; however, this approach excludes assessor bias. We acknowledge the limitation of the data on long-term pain/discomfort: further qualitative study is required to assess those participants with pain for severity, relation to the procedure, impact on QoL, and any possible regret. The single-centre design can be seen as a limitation; however, the procedures were performed by six surgeons of varying experience, ensuring the generalisability of the results. The lack of objective assessment for a cure of UI is a limitation of this study.
Interpretation in light of other evidence
The success rate in the E-TOT study is similar to RP-TVT at 10 years: Groutz et al. 20 underwent a telephone followup at 10 years and reported an overall patient-reported success rate of 65%, whereas 78% reported a cure of SUI. Similarly, Aigmueller et al. 21 assessed 140 women at 10 years following RP-TVT, and reported a patientreported cure rate of 57%, with a further 23% reporting an 'improvement'. Svenningsen et al. 22 showed higher patientreported cure rates (76%) at 10 years for a large cohort (n = 483) who underwent RP-TVT.
Two recent observational studies reported the 10-year outcomes for TO-TVT. Serati et al. 7 reported the results of a multicentre study (n = 160); the patient-reported and objective cure rates were 97 and 92%, respectively. Their outcomes were clearly more favourable than the E-TOT study, despite using the same definition of success; however, inside-out TO-TVT was the only procedure performed in their study and their response rate was almost 95%. Ulrich et al. 6 reported the 10-year outcomes for insideout TO-TVT in two centres (n = 71): the patient-reported and objective cure rates were 64 and 69%, respectively. Similarly, Zhang et al. 23 showed the 7-year patient-reported success rate in the inside-out TO-TVT (n = 62) to be 61.3%. Compared with the E-TOT, the latter two studies used a stricter definition for patient-reported success (no leakage). We did not find any significant differences in patientreported outcomes between inside-out and outside-in TO-TVT; this is consistent with the current literature on shorter term outcomes. 24 The Cochrane review reported that the outcomes for all SUI procedures seem to decline over time. 25 A similar trend was seen in the E-TOT study, with a significant reduction in patient-reported success rate at 9 years compared with 1 year; however, the outcomes were relatively stable after 3 years. Similarly, 25 participants (8%) underwent further continence surgery. Of those, only 1% (n = 3) were treated after the first 3 years. Based on the results of the E-TOT study, clinicians can confidently counsel women that successful outcomes at 3 years are most likely to be retained at 9 years. In the E-TOT study, the re-operation rate was similar to the 7.0 and 7.8% reported by Ulrich et al. and Aigmueller et al. at 10 years following TO-TVT and RP-TVT, respectively. 6, 21 However, other studies have reported higher re-operation rates following TO-TVT. 19, 26 Multivariate analysis in the E-TOT study did not show any independent risk factors for late failures. Previous continence surgery and low MUCP were independent risk factors for TO-TVT failure at 1 year of follow-up. 8 Recently, Serati et al. 7 found previous continence surgery to be the only risk factor for TO-TVT failure at 10 years of followup. Liapis et al., 27 however, showed that low MUCP did not affect the success rates of repeat RP-TVT, whereas a combination of low MUCP and limited urethral mobility were associated with a significantly reduced success rate.
Emphasis has been recently focused on the adverse events associated with the use of mesh in pelvic floor surgery. There is a general concern for the possible underreporting of adverse events; hence, we analysed the adverse events among respondents only to avoid such underestimation.
The rate of de-novo urgency in the E-TOT study was 9.6% at 9 years, which was almost identical to the 9.68% reported by Zhang et al. 23 at 7 years of follow-up for the inside-out TO-TVT. Serati et al. 7 reported a higher denovo urgency rate (14%) at 10 years following inside-out TO-TVT, whereas Ulrich et al. 6 reported 26% at the same follow-up period. It is well recognised that OAB symptoms tend to wax and wane, and the incidence increases with age. 28 Hence on assessing urgency in long-term follow-up studies, it can be difficult to ascertain whether it is related to the MUS or to advancing age, or is a progression of an underlying pathology.
Groin pain
In the E-TOT study, 4% of the respondents reported groin or thigh pain/discomfort, and were almost equally distributed between both TO-TVT approaches: only 1.4% required either medical or surgical treatment. In some patients, these symptoms began almost 6-7 years after the operation, leading to uncertainty about its relationship with the procedure. The lack of a control group (without surgery) introduces further uncertainty; however, chronic groin pain is a recognised adverse event for TO-TVT. Zhang et al. 23 and Ulrich et al. 6 reported 6.4 and 9% groin/inguinal pain/ discomfort at 7 and 10 years of follow-up, respectively. The current evidence therefore tends to confirm that TO-TVT is associated with long-term groin pain/discomfort. Intractable suprapubic pain has also been previously described following colposuspension, and is known as post-colposuspension syndrome. Interestingly, a recent long-term follow-up RCT comparing RP-TVT with autologous fascial slings (AFSs) showed a 3.2% incidence of scar pain in the non-mesh alternative arm (AFS), suggesting that chronic pain is not just a problem experienced with mesh grafts. 29 
Tape erosion/extrusion
Our results are consistent with those of Ulrich et al. and Zhang et al. that vaginal tape erosion/extrusion can occur at a late stage, and surgeons need to be vigilant for this possibility. 6, 23 In our experience, we treat tape extrusion with excision of the eroded part, as we don't find conservative treatment successful. Our results exclude possible asymptomatic tape erosions/extrusions.
Quality of life (QoL) and sexual function can be quite complicated to assess at long-term follow-up, as many other confounding factors may have developed in participants' lives. The use of disease-specific questionnaires can help to overcome this issue to an extent. Similar to the E-TOT results at 1 and 3 years, clinically significant improvement in women's QoL was seen in the majority of women (76%) at a median of 9 years of follow-up. Our findings concur with those of Ulrich et al. and Serrati et al., who reported a significant improvement in most QoL domains at 10 years of follow-up following TO-TVT. 6, 7 The current evidence therefore tends to confirm that the successful outcome of TO-TVT can have a long-lasting positive effect on women's QoL.
Only 87 women completed the sexual function questionnaire; however, this is the largest cohort assessing sexual function following TO-TVT at such long-term follow-up. The majority of women (61%) reported an improvement in sexual function; however, there is an apparent deterioration for one-third of the participants. Several confounding factors may have occurred in that decade of follow-up that would inevitably impact women's sexual function, such as advancing age, development of prolapse, and menopausal vaginal dryness.
Conclusions
This is the largest and longest follow-up RCT of TO-TVT. TO-TVT is associated with 71.6% patient-reported success rate, 4% groin pain/discomfort, and 8% continence reoperation rate for TO-TVT at a median of 9 years of follow-up; the success rate is almost stable after 3 years.
Practical recommendations
Patients can be counselled that the success rate for TO-TVT is almost stable after 3 years, around 71%, and the risk of chromic groin pain is 4%, with 1.4% requiring medical or surgical treatment.
Research recommendations
Qualitative study is required to assess those participants with pain for severity, relationship with the procedure, impact on QoL, and any regret.
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